Table 1 Baseline characteristics of 62 MSI-H CRC patients receiving PD-1 blockade
| Â | With inflammatory conditions | Without inflammatory conditions |
|---|---|---|
Total | 14 | 48 |
Gender | ||
Male | 9 (64.3%) | 33 (68.8%) |
Female | 5 (35.7%) | 15 (31.2%) |
Median age (range) | 34 (20~73) | 46 (19~67) |
Family history | ||
Yes | 6 (42.9%) | 28 (58.3%) |
No | 8 (57.1%) | 20 (41.7%) |
Histology | ||
Adenocarcinoma | 10 (71.4%) | 40 (83.3%) |
Mucinous Adenocarcinoma | 4 (28.6%) | 8 (16.7%) |
Receiving PD-1 blockade combined with non-ICI drugs | ||
Yes | 9 (64.3%) | 21 (43.8%) |
No | 5 (35.7%) | 27 (56.2%) |
